Edesa Biotech Receives C$14 million for COVID-19 Study

Retrieved on: 2021-02-02 17:15:00

Tags for this article:

Health sciences

Health

Medicine

Clinical research

Pharmaceutical industry

Medical research

Drug discovery

Acute respiratory distress syndrome

Intensive care medicine

Coronavirus disease

Severe acute respiratory syndrome

TLR4

Edesa Biotech Inc.

Canada

Click the tags to see associated articles and topics

Edesa Biotech Receives C$14 million for COVID-19 Study. View article details on HISWAI: https://www.biospace.com/article/releases/edesa-biotech-receives-c-14-million-for-covid-19-study/

Excerpt

EB05 is an experimental monoclonal antibody that Edesa believes could ... The company is developing late-stage monoclonal antibodies that block ...

Article found on: www.biospace.com

View Original Article